470 related articles for article (PubMed ID: 29412817)
1. Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents.
Gasbjerg LS; Gabe MBN; Hartmann B; Christensen MB; Knop FK; Holst JJ; Rosenkilde MM
Peptides; 2018 Feb; 100():173-181. PubMed ID: 29412817
[TBL] [Abstract][Full Text] [Related]
2. The role of GIP in α-cells and glucagon secretion.
El K; Campbell JE
Peptides; 2020 Mar; 125():170213. PubMed ID: 31785304
[TBL] [Abstract][Full Text] [Related]
3. Blockade of gastric inhibitory polypeptide (GIP) action as a novel means of countering insulin resistance in the treatment of obesity-diabetes.
Irwin N; Gault VA; O'Harte FPM; Flatt PR
Peptides; 2020 Mar; 125():170203. PubMed ID: 31733230
[TBL] [Abstract][Full Text] [Related]
4. GIP(3-30)NH
Gasbjerg LS; Christensen MB; Hartmann B; Lanng AR; Sparre-Ulrich AH; Gabe MBN; Dela F; Vilsbøll T; Holst JJ; Rosenkilde MM; Knop FK
Diabetologia; 2018 Feb; 61(2):413-423. PubMed ID: 28948296
[TBL] [Abstract][Full Text] [Related]
5. GIP-derived GIP receptor antagonists - a review of their role in GIP receptor pharmacology.
Rosenkilde MM; Lindquist P; Kizilkaya HS; Gasbjerg LS
Peptides; 2024 Jul; 177():171212. PubMed ID: 38608836
[TBL] [Abstract][Full Text] [Related]
6. GIP(3-30)NH
Sparre-Ulrich AH; Gabe MN; Gasbjerg LS; Christiansen CB; Svendsen B; Hartmann B; Holst JJ; Rosenkilde MM
Biochem Pharmacol; 2017 May; 131():78-88. PubMed ID: 28237651
[TBL] [Abstract][Full Text] [Related]
7. Disruption of GIP/GIPR axis in human adipose tissue is linked to obesity and insulin resistance.
Ceperuelo-Mallafré V; Duran X; Pachón G; Roche K; Garrido-Sánchez L; Vilarrasa N; Tinahones FJ; Vicente V; Pujol J; Vendrell J; Fernández-Veledo S
J Clin Endocrinol Metab; 2014 May; 99(5):E908-19. PubMed ID: 24512489
[TBL] [Abstract][Full Text] [Related]
8. Structural and pharmacological characterization of novel potent and selective monoclonal antibody antagonists of glucose-dependent insulinotropic polypeptide receptor.
Ravn P; Madhurantakam C; Kunze S; Matthews E; Priest C; O'Brien S; Collinson A; Papworth M; Fritsch-Fredin M; Jermutus L; Benthem L; Gruetter M; Jackson RH
J Biol Chem; 2013 Jul; 288(27):19760-72. PubMed ID: 23689510
[TBL] [Abstract][Full Text] [Related]
9. A novel GLP-1/xenin hybrid peptide improves glucose homeostasis, circulating lipids and restores GIP sensitivity in high fat fed mice.
Hasib A; Ng MT; Khan D; Gault VA; Flatt PR; Irwin N
Peptides; 2018 Feb; 100():202-211. PubMed ID: 29412820
[TBL] [Abstract][Full Text] [Related]
10. The influence of Glucose-dependent Insulinotropic Polypeptide (GIP) on human adipose tissue and fat metabolism: Implications for obesity, type 2 diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD).
Thondam SK; Cuthbertson DJ; Wilding JPH
Peptides; 2020 Mar; 125():170208. PubMed ID: 31759125
[TBL] [Abstract][Full Text] [Related]
11. Effects on pancreatic Beta and other Islet cells of the glucose-dependent insulinotropic polypeptide.
Khan R; Tomas A; Rutter GA
Peptides; 2020 Mar; 125():170201. PubMed ID: 31751656
[TBL] [Abstract][Full Text] [Related]
12. Human epicardial adipose tissue expresses glucose-dependent insulinotropic polypeptide, glucagon, and glucagon-like peptide-1 receptors as potential targets of pleiotropic therapies.
Malavazos AE; Iacobellis G; Dozio E; Basilico S; Di Vincenzo A; Dubini C; Menicanti L; Vianello E; Meregalli C; Ruocco C; Ragni M; Secchi F; Spagnolo P; Castelvecchio S; Morricone L; Buscemi S; Giordano A; Goldberger JJ; Carruba M; Cinti S; Corsi Romanelli MM; Nisoli E
Eur J Prev Cardiol; 2023 Jun; 30(8):680-693. PubMed ID: 36799940
[TBL] [Abstract][Full Text] [Related]
13. Understanding interactions of gastric inhibitory polypeptide (GIP) with its G-protein coupled receptor through NMR and molecular modeling.
Malde AK; Srivastava SS; Coutinho EC
J Pept Sci; 2007 May; 13(5):287-300. PubMed ID: 17437246
[TBL] [Abstract][Full Text] [Related]
14. Genetic determinants of circulating GIP and GLP-1 concentrations.
Almgren P; Lindqvist A; Krus U; Hakaste L; Ottosson-Laakso E; Asplund O; Sonestedt E; Prasad RB; Laurila E; Orho-Melander M; Melander O; Tuomi T; Holst JJ; Nilsson PM; Wierup N; Groop L; Ahlqvist E
JCI Insight; 2017 Nov; 2(21):. PubMed ID: 29093273
[TBL] [Abstract][Full Text] [Related]
15. Glucose-dependent insulinotropic polypeptide confers early phase insulin release to oral glucose in rats: demonstration by a receptor antagonist.
Lewis JT; Dayanandan B; Habener JF; Kieffer TJ
Endocrinology; 2000 Oct; 141(10):3710-6. PubMed ID: 11014226
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a potent GIPR peptide antagonist that is effective in rodent and human systems.
Yang B; Gelfanov VM; El K; Chen A; Rohlfs R; DuBois B; Kruse Hansen AM; Perez-Tilve D; Knerr PJ; D'Alessio D; Campbell JE; Douros JD; Finan B
Mol Metab; 2022 Dec; 66():101638. PubMed ID: 36400403
[TBL] [Abstract][Full Text] [Related]
17. The pathogenic role of the GIP/GIPR axis in human endocrine tumors: emerging clinical mechanisms beyond diabetes.
Regazzo D; Barbot M; Scaroni C; Albiger N; Occhi G
Rev Endocr Metab Disord; 2020 Mar; 21(1):165-183. PubMed ID: 31933128
[TBL] [Abstract][Full Text] [Related]
18. Effects of endogenous GIP in patients with type 2 diabetes.
Stensen S; Gasbjerg LS; Krogh LL; Skov-Jeppesen K; Sparre-Ulrich AH; Jensen MH; Dela F; Hartmann B; Vilsbøll T; Holst JJ; Rosenkilde MM; Christensen MB; Knop FK
Eur J Endocrinol; 2021 May; 185(1):33-45. PubMed ID: 33886495
[TBL] [Abstract][Full Text] [Related]
19. Coingestion of acylglycerols differentially affects glucose-induced insulin secretion via glucose-dependent insulinotropic polypeptide in C57BL/6J mice.
Shimotoyodome A; Fukuoka D; Suzuki J; Fujii Y; Mizuno T; Meguro S; Tokimitsu I; Hase T
Endocrinology; 2009 May; 150(5):2118-26. PubMed ID: 19179446
[TBL] [Abstract][Full Text] [Related]
20. Twincretin as a potential therapeutic for the management of type 2 diabetes with obesity.
Usui R; Yabe D; Seino Y
J Diabetes Investig; 2019 Jul; 10(4):902-905. PubMed ID: 30637966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
